
TY  - JOUR
TI  - Abstracts
JO  - Journal of Cardiovascular Electrophysiology
JA  - Wound Repair Regen
VL  - 18
IS  - s2
SN  - 1045-3873
UR  - https://doi.org/10.1111/j.1540-8167.2007.00933_1.x
DO  - doi:10.1111/j.1540-8167.2007.00933_1.x
SP  - S1
EP  - S68
PY  - 2007
ER  - 

TY  - JOUR
TI  - ASBMR 29th Annual Meeting
JO  - Wound Repair and Regeneration
JA  - J Bone Miner Res
VL  - 20
IS  - 5
SN  - 1067-1927
UR  - https://doi.org/10.1111/j.1524-475X.2012.00835.x
DO  - doi:10.1111/j.1524-475X.2012.00835.x
SP  - A53
EP  - A78
PY  - 2012
ER  - 

TY  - JOUR
TI  - METABOLIC AND CRYSTAL ARTHROPATHIES
JO  - Journal of Bone and Mineral Research
VL  - 22
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650221412
DO  - doi:10.1002/jbmr.5650221412
SP  - s501
EP  - s510
PY  - 2007
ER  - 

TY  - JOUR
TI  - OSTEOARTHRITIS – CLINICAL ASPECTS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_15.x
DO  - doi:10.1111/j.1479-8077.2006.00199_15.x
SP  - A83
EP  - A90
PY  - 2006
ER  - 

TY  - JOUR
TI  - ANTI-PHOSPHOLIPID SYNDROME
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_19.x
DO  - doi:10.1111/j.1479-8077.2006.00199_19.x
SP  - A108
EP  - A125
PY  - 2006
ER  - 

TY  - JOUR
TI  - PAEDIATRIC RHEUMATOLOGY
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_2.x
DO  - doi:10.1111/j.1479-8077.2006.00199_2.x
SP  - A25
EP  - A26
PY  - 2006
ER  - 

TY  - JOUR
TI  - RHEUMATOID ARTHRITIS – TREATMENT
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_22.x
DO  - doi:10.1111/j.1479-8077.2006.00199_22.x
SP  - A159
EP  - A167
PY  - 2006
ER  - 

TY  - JOUR
TI  - SJOGREN'S SYNDROME
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_24.x
DO  - doi:10.1111/j.1479-8077.2006.00199_24.x
SP  - A188
EP  - A210
PY  - 2006
ER  - 

TY  - JOUR
TI  - 18th Annual Meeting of the Wound Healing Society SAWC/WHS Joint Meeting
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_27.x
DO  - doi:10.1111/j.1479-8077.2006.00199_27.x
SP  - A230
EP  - A234
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Wound Repair and Regeneration
JA  - Basic Clin Pharmacol Toxicol
VL  - 16
IS  - 2
SN  - 1067-1927
UR  - https://doi.org/10.1111/j.1524-475X.2008.00371.x
DO  - doi:10.1111/j.1524-475X.2008.00371.x
SP  - A10
EP  - A58
PY  - 2008
ER  - 

TY  - JOUR
TI  - 2012 ACVIM Forum Research Abstracts Program
JO  - Basic & Clinical Pharmacology & Toxicology
JA  - J Vet Intern Med
VL  - 119
IS  - S2
SN  - 1742-7835
UR  - https://doi.org/10.1111/bcpt.12659
DO  - doi:10.1111/bcpt.12659
SP  - 3
EP  - 37
PY  - 2016
ER  - 

TY  - JOUR
AU  - Gala, Salvador
AU  - Fulcher, David A
TI  - 3.4 How HIV leads to autoimmune disorders
JO  - Journal of Veterinary Internal Medicine
JA  - Medical Journal of Australia
VL  - 26
IS  - 3
SN  - 0891-6640
UR  - https://doi.org/10.1111/j.1939-1676.2012.00937.x
DO  - doi:10.1111/j.1939-1676.2012.00937.x
SP  - 690
EP  - 822
PY  - 2012
AB  - HIV-related autoimmune disorders tend to occur in the early phase of HIV infection, while the immune system is still relatively competent, and they may be the presenting manifestation of HIV infection itself.
ER  - 

TY  - JOUR
AU  - TRIPODI, A.
AU  - ANSTEE, Q. M.
AU  - SOGAARD, K. K.
AU  - PRIMIGNANI, M.
AU  - VALLA, D. C.
TI  - Hypercoagulability in cirrhosis: causes and consequences1
JO  - Medical Journal of Australia
VL  - 164
IS  - 4
SN  - 0025-729X
UR  - https://doi.org/10.5694/j.1326-5377.1996.tb94145.x
DO  - doi:10.5694/j.1326-5377.1996.tb94145.x
SP  - 224
EP  - 226
KW  - chronic liver disease
KW  - factor VIII
KW  - protein C
KW  - thrombin
KW  - thrombomodulin
PY  - 1996
AB  - Summary.? Decreased levels of most coagulation factors and thrombocytopenia are the main haemostatic abnormalities of cirrhosis. As a consequence, this condition was, until recently, considered as the prototype acquired coagulopathy responsible for bleeding. However, recent evidence suggests that it should, rather, be regarded as a condition associated with normal or even increased thrombin generation. The bleeding events that occur in these patients should, therefore, be explained by the superimposed conditions that frequently occur in this setting. Due to elevated levels of factor VIII (procoagulant driver) in combination with decreased protein C (anticoagulant driver), which are typically found in patients with cirrhosis, a procoagulant imbalance, defined as a partial resistance to the in vitro anticoagulant action of thrombomodulin, can be demonstrated. Whether this in vitro hypercoagulability is truly representative of what occurs in vivo remains to be established. However, the hypothesis that it may have clinical consequences is attractive and deserves attention. The possible consequences that we discuss herein include whether (i) cirrhosis is a condition associated with increased risk of venous thromboembolism or portal vein thrombosis; (ii) the hypercoagulability associated with cirrhosis has any other role outside coagulation (i.e. progression of liver fibrosis); and (iii) anticoagulation should be used in cirrhosis. Although apparently provocative, considering anticoagulation as a therapeutic option in patients with cirrhosis is now supported by a rationale of increasing strength. There may be subgroups of patients who benefit from anticoagulation to treat or prevent thrombosis and to slow hepatic fibrosis. Clinical studies are warranted to explore these therapeutic options.
ER  - 

TY  - JOUR
TI  - Abstracts—Symposia
JO  - Journal of Thrombosis and Haemostasis
VL  - 9
IS  - 9
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2011.04429.x
DO  - doi:10.1111/j.1538-7836.2011.04429.x
SP  - 1713
EP  - 1723
PY  - 2011
ER  - 

TY  - JOUR
TI  - Index
JO  - Alcoholism: Clinical and Experimental Research
JA  - Goldstein/A Primer on Stroke Prevention Treatment
VL  - 35
IS  - s1
SN  - 0145-6008
UR  - https://doi.org/10.1111/j.1530-0277.2011.01498.x
DO  - doi:10.1111/j.1530-0277.2011.01498.x
SP  - 263A
EP  - 316A
PY  - 2011
ER  - 

C7  - pp. 247-259
TI  - Poster
SN  - 9781405186513
UR  - https://doi.org/10.1002/9781444308198.index
DO  - doi:10.1002/9781444308198.index
SP  - 247-259
PY  - 2011
ER  - 

TY  - JOUR
TI  - PAPERS BY AUTHOR
JO  - Psycho-Oncology
JA  - Annals of the New York Academy of Sciences
VL  - 29
IS  - S1
SN  - 9781405186513
UR  - https://doi.org/10.1002/pon.5328
DO  - doi:10.1002/pon.5328
SP  - 66
EP  - 117
PY  - 2020
ER  - 

TY  - JOUR
TI  - SYMPOSIA
JO  - Annals of the New York Academy of Sciences
VL  - 634
IS  - 1
SN  - 9781405186513
UR  - https://doi.org/10.1111/j.1749-6632.1992.tb00008.x
DO  - doi:10.1111/j.1749-6632.1992.tb00008.x
SP  - 7
EP  - 179
PY  - 1992
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Fundamental & Clinical Pharmacology
VL  - 13
IS  - S1
SN  - 9781405186513
UR  - https://doi.org/10.1111/j.1472-8206.1999.tb00382.x
DO  - doi:10.1111/j.1472-8206.1999.tb00382.x
SP  - 11s
EP  - 113s
PY  - 1999
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Journal of Paediatrics and Child Health
VL  - 44
IS  - s1
SN  - 9781405186513
UR  - https://doi.org/10.1111/j.1440-1754.2008.01299.x
DO  - doi:10.1111/j.1440-1754.2008.01299.x
SP  - A80
EP  - A117
PY  - 2008
ER  - 
